Opinion

Video

Adjuvant RSV Vaccine in Older Adults

Author(s):

Carrie Koenigsfeld, PharmD, FAPhA

Carrie Koenigsfeld, PharmD, FAPhA, reviews the pivotal findings from the AReSVi-006 trial that supported the approval of the adjuvanted RSV vaccine, including its efficacy in preventing lower respiratory tract RSV, associated adverse events, and important study limitations that may have influenced the results.

  1. While the follow-up data for the AReSVi-006 trial have not been published, what key results thus far have led to the approval of the adjuvanted vaccine?
    1. Efficacy of preventing RSV-related lower respiratory tract disease
    2. Adverse effects
    3. Trial limitations

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
Doctor making a vaccination - Image credit: guerrieroale | stock.adobe.com
September 4th 2025

New Clinical Guidance Recommends Vaccines to Protect Cardiovascular Patients From Respiratory Illness

Kennedy Ferruggia, Assistant Editor
MEDcast logo
September 4th 2025

Key Considerations for the Effective Utilization of RSV Vaccines

Ashley Pugh, PharmD, BCACP Lauren B. Angelo, PharmD, MBA
Abrysvo RSV vaccine, Respiratory Syncytial Virus vaccination for pregnant women, Australian immunisation program 2025, Queensland General PracticeImage credit: Cynthia | stock.adobe.com
September 4th 2025

RSVpreF Vaccine Is Well-Tolerated in Adults, Demonstrating Favorable Safety Profile

Kennedy Ferruggia, Assistant Editor
RSV vaccine vial with syringe - Respiratory syncytial virus shot - Image credit: MargJohnsonVA | stock.adobe.com
September 4th 2025

RSV Vaccine Uptake Remains Low Among US Adults 60 Years and Older

Kennedy Ferruggia, Assistant Editor
RSV positive test result by using rapid test cassette, diagnosis for respiratory disease - Image credit: jarun011 | stock.adobe.com
September 4th 2025

Researchers Evaluate Infection Control Challenges During an RSV Outbreak in a Cognitively Impaired Population

Kennedy Ferruggia, Assistant Editor
Respiratory syncytial virus or RSV, 3d rendering medical illustration, or human orthopneumovirus - Image credit: Josh | stock.adobe.com
September 4th 2025

Researchers Assess Cardiovascular Outcomes in Older Adults Hospitalized With Respiratory Syncytial Virus

Kennedy Ferruggia, Assistant Editor
© 2025 MJH Life Sciences

All rights reserved.